Wilate is approved by the Food and Drug Administration (FDA) for on-demand treatment and control of bleeding episodes in children and adults with von Willebrand disease. Wilate can also be used for perioperative (before, during, and after surgery) care. The technical name of Wilate is von Willebrand factor/Coagulation factor VIII complex (human).
Wilate is a clotting factor. Clotting factors work by supplying proteins missing in people with bleeding disorders.
How do I take it?
Prescribing information states that Wilate is given as an intravenous injection.
Wilate comes as a powder that must be reconstituted before injection.
The FDA-approved label for Wilate lists common side effects including dizziness, hives, and hypersensitivity reactions.
Rare but serious side effects listed for Wilate include life-threatening hypersensitivity reactions, thromboembolic events (dangerous blood clots), the risk for transmission of infectious diseases, and the development of inhibitors.
For more details about this treatment, visit:
Treatment of Hemophilia – Hemophilia Federation of America